Mona Al Mukaddam, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1043400567
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,534 of the $7,559 with a category attached, or 99.7%. Ipsen Biopharmaceuticals, Inc accounts for 99.2% of it on its own, with 2 other manufacturers making up the rest.
Across 6 payments — averaging $1259.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$8K
- Shire North American Group Inc$34
- Ipsen Biopharm Limited$25
Across 490 payments — averaging $7852.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Bioscience Inc.$1.5M
- Incyte Corporation$1.1M
- Regeneron$781K
- Ipsen Innovation$317K
- Ipsen Pharma SAS$81K
- Ipsen Biopharmaceuticals, Inc$5K
What the payments were for
- Food & beverage$250%
- Education$7,534100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 4 | $7,500 |
| Shire North American Group Inc | 1 | $34 |
| Ipsen Biopharm Limited | 1 | $25 |
How this compares
$7,559 in reported general payments places this provider in the 75th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActimmuneInterferon Gamma-1b,recomb. | 14 | $901,791 |
| TymlosAbaloparatide | 248 | $657,811 |
| CrysvitaBurosumab-Twza | 11 | $325,521 |
| ForteoTeriparatide | 51 | $206,812 |
| Teriparatide | 34 | $76,068 |
| ProliaDenosumab | 17 | $28,784 |
| Cinacalcet Hcl | 24 | $8,237 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 66 | $3,602 |
| SynthroidLevothyroxine Sodium | 34 | $3,137 |
| Alendronate Sodium | 113 | $2,733 |
| Risedronate Sodium | 27 | $1,604 |
| Calcitriol | 26 | $589 |
| Levothyroxine Sodium | 45 | $544 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.